Provides an AI-powered platform, MoleculeGEN, for de novo drug design and antibody generation, leveraging deep learning and biophysics to create novel small molecules and antibodies tailored to specific disease targets. This approach addresses the challenges of traditional drug discovery by automating hit generation, lead optimization, and toxicity prediction, enabling faster development of treatments for diseases with high unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery methods are often slow, expensive, and have a low success rate due to the vast chemical space and complex biological interactions involved. Identifying promising drug candidates and optimizing their properties requires extensive experimental screening and iterative refinement, leading to long development timelines and high costs.
Solution
MoleculeGEN is an AI-powered platform that accelerates drug discovery by automating de novo drug design and antibody generation. The platform leverages deep learning and biophysics-based algorithms to create novel small molecules and antibodies tailored to specific disease targets. By integrating target information, generative AI, and ADME/Tox prediction, MoleculeGEN streamlines hit generation, lead optimization, and toxicity assessment. The platform's integrated approach enables researchers to efficiently explore the chemical space, identify promising drug candidates with desired properties, and accelerate the development of treatments for diseases with unmet medical needs.
Target Audience
The primary audience includes pharmaceutical companies, biotechnology firms, and research institutions involved in drug discovery and development.
Features
- De novo molecule generation: Creates novel, drug-like small molecules for specific targets using AI-driven computational tools.
- Antibody design: Applies AI capabilities in screening and de novo generation of antibodies against challenging targets.
- Target-aware molecule generation: Generates molecules specifically designed to interact with a given target protein.
- Hit to lead and lead optimization: Refines initial hit compounds into optimized lead candidates with improved properties.
- ADME/Toxicity prediction: Predicts absorption, distribution, metabolism, excretion, and toxicity properties of molecules.
- Protein-ligand interaction visualization: Provides an interface to visualize proteins, ligands, and their interactions.
- Curated protein metadata access: Offers access to curated metadata and analyses for proteins.